Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has earned an average rating of “Buy” from the twenty-seven ratings firms that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $154.24.

A number of brokerages recently issued reports on ALXN. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a research report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 target price on the stock in a research report on Friday, July 28th. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 target price on the stock. Morgan Stanley reissued an “overweight” rating and issued a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, July 14th.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Given Average Rating of “Buy” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/27/alexion-pharmaceuticals-inc-alxn-given-average-rating-of-buy-by-brokerages.html.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 126.07 on Friday. The firm has a market cap of $28.14 billion, a P/E ratio of 54.67 and a beta of 1.39. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a 50-day moving average price of $141.58 and a 200-day moving average price of $128.29.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 25th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the previous year, the business posted $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.60 earnings per share for the current year.

In related news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold a total of 17,190 shares of company stock worth $2,433,669 over the last three months. 4.35% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commerzbank Aktiengesellschaft FI boosted its stake in Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock valued at $16,145,000 after purchasing an additional 79,943 shares during the period. HPM Partners LLC boosted its stake in Alexion Pharmaceuticals by 267.2% in the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 4,861 shares during the period. Principal Financial Group Inc. boosted its stake in Alexion Pharmaceuticals by 1.2% in the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after purchasing an additional 4,115 shares during the period. Ameriprise Financial Inc. boosted its stake in Alexion Pharmaceuticals by 0.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock valued at $751,363,000 after purchasing an additional 25,724 shares during the period. Finally, Calamos Advisors LLC boosted its stake in Alexion Pharmaceuticals by 405.3% in the 2nd quarter. Calamos Advisors LLC now owns 334,488 shares of the biopharmaceutical company’s stock valued at $40,697,000 after purchasing an additional 268,287 shares during the period. Institutional investors and hedge funds own 94.15% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.